GSK’s Arexvy Leads Over Pfizer’s Abrysvo in Year One of RSV Vaccine Market Battle
XTalks
FEBRUARY 5, 2024
Morgan Healthcare Conference in January, Pfizer CEO Albert Bourla said the RSV shot was a “bad launch” for the company. The RSV vaccine market is anticipated to undergo significant growth, with projections by GlobalData suggesting an expansion from $1.2 At the J.P. billion in 2022 to $9 billion by 2029.
59 
Let's personalize your content